

Efficacy and safety of S 38093 versus placebo in patients with mild to moderate Alzheimer's disease

Submission date 20/05/2011	Recruitment status No longer recruiting	☒ Prospectively registered
		☐ Protocol
Registration date 28/07/2011	Overall study status Completed	☐ Statistical analysis plan
		☒ Results
Last Edited 20/04/2020	Condition category Mental and Behavioural Disorders	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Prof Bruno Vellas

Contact details

C.H.U. La Grave-Casselardit
Service de Medecine Interne et de Gerontologie Clinique
170 Avenue de Casselardit
TSA 60033
Toulouse
France
31059

Additional identifiers

Clinical Trials Information System (CTIS)

2010-024626-37

Protocol serial number

CL2-38093-011

Study information

Scientific Title

Efficacy and safety of three doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer's disease

Study objectives

To demonstrate efficacy of at least one dose of S 38093 as compared to placebo on primary endpoint

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Primary study design

Interventional

Study design

A 24-week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study followed by a 24-week extension period

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Mild to moderate Alzheimer's disease

Interventions

1. 2, 5 or 20mg/day of S 38093 or placebo, orally, during a 24-week treatment period + 24-week treatment extension period
2. A 2-6-week selection period without study treatment will be followed by a 24-week double-blind treatment with 4-parallel groups (doses : 2, 5 and 20 mg/day of S38093 and placebo) and a 24-week optional treatment extension period (patients on placebo will be re-randomised to S 38093 2; 5 or 20mg) and a 2-week follow-up period
3. One tablet of S 38093 (2, 5 or 20mg) or placebo will be taken orally, once a day, during study participation from inclusion visit +1 until follow-up period

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

S 38093

Primary outcome(s)

1. The Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) 11-items
2. ADAS-Cog will be assessed at week 0, week 24, week 36 and week 48

Key secondary outcome(s)

1. Disability Assessment for Dementia (DAD)
2. DAD will be assessed at week 0, week 24 and week 48

Completion date

30/04/2014

Eligibility**Key inclusion criteria**

1. Age 55-85 years
2. School education more than or equal to 4 years
3. Able to perform neuropsychological tests
4. Have adequate visual and auditory acuity with the usual corrective aids to allow neuropsychological testing
5. Have a responsible informant Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for Dementia of the Alzheimer's type
6. National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable Alzheimer's disease (AD)
7. Mini-Mental State Examination (MMSE) between 15 and 24

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

711

Key exclusion criteria

1. Inpatients
2. Female patients of child-bearing potential
3. Dementia due to any condition other than AD
4. History of epilepsy or solitary seizure
5. History or presence of Parkinson's disease or Parkinsonism
6. Major neurological or neurodegenerative conditions associated with significant cognitive impairment such as Multiple Sclerosis or Huntington's Disease
7. Major psychiatric conditions

Date of first enrolment

22/08/2011

Date of final enrolment

30/04/2014

Locations

Countries of recruitment

Australia

Brazil

Bulgaria

Chile

Czech Republic

France

Germany

Hungary

Mexico

Portugal

Romania

Russian Federation

South Africa

Study participating centre

CHU La Grave-Casselardit

Toulouse

France

31059

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

ROR

<https://ror.org/034e7c066>

Funder(s)

Funder type

Industry

Funder Name

Institut de Recherches Internationales Servier (France)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com> if a Marketing Authorisation has been granted after 1st January 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No
Basic results			20/04/2020	No	No